Financial Summary (All financials)
| In millions, except per share items | Jan-02-22 | Jan-03-21 | Dec-29-19 | Dec-30-18 | Dec-31-17 | Jan-01-17 | Jan-03-16 | Dec-28-14 |
| Revenues | 1,897.0 | 1,733.8 | 1,709.0 | 1,589.9 | 1,223.4 | 1,435.4 | 1,870.3 | 1,998.5 |
| Revenue growth | 9.4% | 1.5% | 7.5% | 30.0% | -14.8% | -23.3% | -6.4% | -17.5% |
| Cost of goods sold | 611.7 | 614.9 | 597.5 | 548.6 | 517.9 | 759.0 | 1,184.1 | 1,355.1 |
| Gross profit | 1,285.3 | 1,118.9 | 1,111.5 | 1,041.3 | 705.5 | 676.5 | 686.2 | 643.4 |
| Gross margin | 67.8% | 64.5% | 65.0% | 65.5% | 57.7% | 47.1% | 36.7% | 32.2% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 42.9 | 26.5 | 43.7 | 25.2 | 16.3 | | | |
| General and administrative | 243.0 | 206.9 | 200.2 | 217.5 | 203.6 | 236.8 | 256.6 | 260.7 |
| EBITA | 399.5 | 342.8 | 338.4 | 315.3 | 327.8 | 318.0 | 302.1 | 244.9 |
| EBITA margin | 21.1% | 19.8% | 19.8% | 19.8% | 26.8% | 22.2% | 16.2% | 12.3% |
| Amortization of intangibles | 55.2 | 52.6 | 53.2 | 52.1 | 47.3 | 48.8 | 54.7 | 42.3 |
| EBIT | 344.2 | 290.2 | 285.3 | 263.2 | 280.5 | 269.2 | 247.4 | 202.6 |
| EBIT margin | 18.1% | 16.7% | 16.7% | 16.6% | 22.9% | 18.8% | 13.2% | 10.1% |
| Pre-tax income | 240.6 | 152.8 | 171.5 | 574.9 | 101.0 | 201.7 | 234.1 | 192.5 |
| Income taxes | 40.2 | 35.0 | 34.5 | 114.8 | -93.0 | 72.1 | 94.1 | 76.1 |
| Tax rate | 16.7% | 22.9% | 20.1% | 20.0% | | 35.7% | 40.2% | 39.5% |
| Earnings from continuing ops | 200.4 | 117.8 | 136.9 | 460.1 | 194.0 | 129.6 | 140.0 | 116.4 |
| Earnings from discontinued ops | | | | | | | 21.2 | 5.0 |
| Net income | 200.4 | 117.8 | 136.9 | 460.1 | 194.0 | 129.6 | 161.1 | 121.4 |
| Net margin | 10.6% | 6.8% | 8.0% | 28.9% | 15.9% | 9.0% | 8.6% | 6.1% |
| |
| Diluted EPS | $0.89 | $0.52 | $0.58 | $1.88 | $0.77 | $0.49 | $0.43 | $0.31 |
| Shares outstanding (diluted) | 224.4 | 228.0 | 235.1 | 245.0 | 252.3 | 266.7 | 328.7 | 376.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|